STOCK TITAN
  1. Home
  2. News
  3. COYA

Coya Therapeutics, Inc. - $COYA STOCK NEWS

Welcome to our dedicated page for Coya Therapeutics news (Ticker: $COYA), a resource for investors and traders seeking the latest updates and insights on Coya Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Coya Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Coya Therapeutics's position in the market.

News
Coya Therapeutics Announces Closing of $26.5 Million Private Placement
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq: COYA) closed a private placement offering of 4,370,382 shares of common stock, raising $26.5 million. Net proceeds are expected to be approximately $24.1 million, intended for general corporate purposes, working capital, and to support preclinical, clinical, and regulatory activities. The financing is anticipated to fund operations into 2026, with participation from former U.S. Secretary of Commerce Wilbur Ross and other existing institutional investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.95%
Tags
none
-
News
Coya Therapeutics Announces $26.5 Million Private Placement
Rhea-AI Summary
Coya Therapeutics, Inc. (Nasdaq:COYA) has entered into definitive securities purchase agreements for the purchase and sale of 4,370,382 shares of its common stock at a purchase price of $6.06 per share in a private placement priced at-the-market under Nasdaq rules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
-
News
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Rhea-AI Summary
Dr. Reddy's Laboratories SA (NYSE: RDY) and Coya Therapeutics, Inc. (NASDAQ: COYA) have entered into a development and license agreement for the commercialization of COYA 302, an investigational combination therapy for the treatment of Amyotrophic Lateral Sclerosis (ALS). The agreement grants Dr. Reddy's the exclusive rights to commercialize COYA 302 in the United States, Canada, the European Union, and the United Kingdom. The agreement includes an upfront payment of USD 7.5 million to Coya, with additional milestone payments of up to USD 40 million and sales-based milestone payments of up to USD 677.25 million. Dr. Reddy's will also pay royalties based on a percentage of net sales of COYA 302 ranging from low to middle teens. The development of COYA 302 was a result of a research collaboration between Coya and Houston Methodist in the laboratory of Dr. Stanley Appel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
none
News
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results
Rhea-AI Summary
COYA (Coya Therapeutics, Inc.) announced Q3 2023 financial results and clinical updates, including completion of enrollment in a Phase 2 study for Alzheimer’s Disease, new data for the treatment of Amyotrophic Lateral Sclerosis, and securing licensing rights for Exosome Engineering Technology (EET) from Carnegie Mellon University. The company also published research articles, appointed new board members and clinical advisors, and provided anticipated events and milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
earnings
-
News
Coya Announces Acceptance of Oral Presentation, “Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimer’s Disease: A Phase 1 Feasibility Study,” at the 18th International Conference on Alzheimer’s and Parkinson’s Disease in Lisbon
Rhea-AI Summary
Coya Therapeutics announces positive results from a study on Low Dose IL-2 in Alzheimer's patients. A double-blind, placebo-controlled study is fully enrolled and will release data in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
clinical trial
-
News
Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease (AD)
Rhea-AI Summary
Coya Therapeutics completes enrollment in phase 2 study of LD IL-2 in patients with mild-to-moderate AD
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
clinical trial
News
Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
Rhea-AI Summary
Coya Therapeutics announces new experimental data on COYA 302 for ALS treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
none
-
News
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium Meeting
Rhea-AI Summary
Coya Therapeutics presents poster highlighting the role of inflammatory cells in ALS and the potential of COYA 302. Combination therapies targeting immune pathways show promise.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
none
-
News
Coya Therapeutics to Present at the LD Micro Investor Conference
Rhea-AI Summary
Coya Therapeutics (COYA) to present at LD Micro Investor Conference on October 3 at 8:00am PT.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.22%
Tags
conferences
News
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)
Rhea-AI Summary
Coya Therapeutics licenses exclusive rights to proprietary Exosome Engineering Technology, expanding potential applications and partnerships
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
none
Stock COYA logo
Coya Therapeutics, Inc.

Nasdaq:COYA

COYA Rankings

#4143 Ranked by Market Cap
#1884 Ranked by Stock Gains
N/A Ranked by Dividends

COYA Stock Data

124.25M
9.97M
7.95%
17.57%
1.31%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
HOUSTON